Race Appoints Damian Clarke-Bruce as CEO & Managing Director
Filed with ASX · · 5 pages · English
Earlier from Racura Oncology
- Positive Pre-IND Guidance from FDA on Zantrene
- Response to ASX Price Query
- Race Develops Improved IV Formulation of Zantrene
- Race Initiates New Drug Discovery Program
- Race Oncology: Update - Notification of buy-back - RAC
Later from Racura Oncology
- Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
- Race supports Study of Extramedullary AML
- Race Receives Cardioprotection Ethics Trial Approval
- New Collaboration to Understand Zantrene Cardioprotection
- Race Executes Contracts to Commence Breast Cancer Trial
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology